TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $40.67.

A number of equities analysts have recently commented on TGTX shares. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright boosted their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. The Goldman Sachs Group raised their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday.

TG Therapeutics Stock Down 0.3 %

Shares of NASDAQ TGTX opened at $32.16 on Friday. The business’s fifty day moving average price is $29.96 and its 200-day moving average price is $24.24. TG Therapeutics has a one year low of $12.84 and a one year high of $36.84. The stock has a market capitalization of $5.01 billion, a PE ratio of -321.57 and a beta of 2.25. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue was down 49.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 EPS. On average, equities research analysts anticipate that TG Therapeutics will post 0.17 EPS for the current year.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. NBC Securities Inc. lifted its position in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the last quarter. Blue Trust Inc. raised its holdings in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics during the 2nd quarter valued at $35,000. ORG Wealth Partners LLC bought a new stake in TG Therapeutics in the 3rd quarter worth $53,000. Finally, Values First Advisors Inc. purchased a new position in shares of TG Therapeutics in the third quarter valued at about $58,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.